What is DNAtrix?
DNAtrix is a privately held biotechnology enterprise specializing in the engineering of oncolytic viruses designed to selectively target and eradicate malignant cells. The company's core technology utilizes an engineered version of the common cold virus, which acts as a precision delivery vehicle for therapeutic payloads. Its lead candidate, DNX-2401, is currently positioned for a global pivotal Phase 3 clinical trial targeting recurrent glioblastoma, a highly aggressive form of brain cancer. Furthermore, the company maintains a diversified pipeline, including DNX-2440, which is undergoing Phase 1 evaluation for metastatic colorectal cancer. By focusing on high-unmet-need indications, DNAtrix has secured significant regulatory support, including FDA Fast Track and Rare Pediatric Disease designations, cementing its position as a high-growth player in the immuno-oncology sector.
How much funding has DNAtrix raised?
DNAtrix has raised a total of $41.9M across 12 funding rounds:
Other Financing Round
$479K
Other Financing Round
$170K
Other Financing Round
$4.5M
Private Equity
$885K
Multiple Rounds
$2.5M
Grant
$10.8M
Series B
$20M
Grant
$2M
Debt
$350K
Other Financing Round (2008): $479K led by Mercury Fund
Other Financing Round (2010): $170K supported by Mercury Fund
Other Financing Round (2012): $4.5M featuring Mercury Fund
Private Equity (2012): $885K, investors not publicly disclosed
Other Financing Round (2013): $160K with participation from Mercury Fund
Other Financing Round (2013): $840K led by Mercury Fund
Series A (2013): $1.5M, investors not publicly disclosed
Grant (2014): $10.8M featuring Cancer Prevention & Research Institute of Texas
Series B (2014): $20M backed by Morningside Ventures, Mercury Fund, and Targeted Technology Fund
Grant (2016): $2M with participation from U.S. Food & Drug Administration
Debt (2020): $350K led by PPP
Key Investors in DNAtrix
Mercury Fund
A venture capital firm focused on early-stage investments in software and life science companies, providing foundational support to high-growth startups.
Targeted Technology Fund
Targeted Technology focuses on early-stage investments in companies that advance groundbreaking or disruptive technologies to enhance medical practices and patient outcomes.
U.S. Food & Drug Administration
The U.S. Food and Drug Administration is a federal public health agency responsible for protecting and promoting public health by regulating medical products and biological therapies.
What's next for DNAtrix?
Looking ahead, the strategic deployment of the $350K will be instrumental in accelerating the global Phase 3 clinical program for DNX-2401. The company is expected to prioritize operational scaling and clinical trial execution to meet the rigorous demands of late-stage regulatory approval. As DNAtrix moves closer to commercialization, the focus will likely shift toward optimizing manufacturing processes for its viral vectors and exploring potential strategic partnerships or licensing agreements to expand the reach of its therapeutic platform. The firm's ability to maintain a consistent growth trajectory, supported by its long-term investor base, positions it favorably for future value creation in the competitive landscape of precision medicine.
See full DNAtrix company page
